Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AccuSite injectable gel: MATX said early results in an open-label Phase II trial in 13 patients already enrolled are promising. The study, which will enroll a t

The trial will end by early July,

Read the full 79 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE